玻璃体纤连蛋白和纤维蛋白原表达在增生性糖尿病视网膜病变抗VEGF治疗后增加
研究纳入需要玻璃体切割术的增生性糖尿病视网膜病变患者,比较术前接受抗VEGF注射、全视网膜光凝和未治疗三组的玻璃体蛋白表达谱,发现抗VEGF组纤连蛋白和纤维蛋白原浓度最高,可能促进纤维蛋白-纤连蛋白复合物形成和纤维化。
要点
- 抗VEGF注射组玻璃体纤连蛋白和纤维蛋白原浓度最高。
- 蛋白质组学显示抗VEGF组纤连蛋白、纤维蛋白原α/β/γ链、VEGFR1和VEGFR2信号强度显著高于其他两组。
- ELISA验证纤连蛋白和纤维蛋白原差异,但VEGF和VEGFR2浓度无显著差异。
核心结论
- 玻璃体纤连蛋白和纤维蛋白原浓度在抗VEGF注射患者中最高,可能促进增生性糖尿病视网膜病变眼的纤维蛋白-纤连蛋白复合物形成和纤维化。
研究设计与样本
- 连续纳入需要玻璃体切割术的增生性糖尿病视网膜病变患者,分抗VEGF注射组(n=12)、全视网膜光凝组(n=29)和未治疗对照组(n=21),收集玻璃体样本进行无标记定量蛋白质组学分析和酶联免疫吸附试验验证。
主要发现
- 抗VEGF组患者平均在玻璃体切割术前5.8天(范围3-8天)接受注射,年龄小于全视网膜光凝组和对照组,三组糖尿病病程相似。
- 无标记定量蛋白质组学显示抗VEGF组纤连蛋白、纤维蛋白原α链、纤维蛋白原β链、纤维蛋白原γ链、VEGFR1和VEGFR2信号强度显著高于其他两组。
- 酶联免疫吸附试验验证了纤连蛋白和纤维蛋白原的结果,但VEGF或VEGFR2浓度无显著差异。
- VEGFR1表达在抗VEGF组和全视网膜光凝组显著高于对照组。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate vitreous humor (VH) protein expression profiles in patients with proliferative diabetic retinopathy (PDR), with and without intravitreal injection (IVI) of anti-vascular endothelial growth factor (anti-VEGF) before vitrectomy. METHODS: We enrolled consecutive PDR patients who needed pars plana vitrectomy (PPV) with or without IVI or pan-retinal photocoagulation (PRP). Visual acuity, duration, and treatment of diabetes mellitus, ocular treatment history, and fundus examinations were recorded. VH samples were collected without artificial humor infusion. Label-free quantitative proteomics analysis was performed to determine the protein expression profiles of VH samples. Enzyme-linked immunosorbent assays were performed to validate the proteomics results. RESULTS: PDR patients who underwent IVI at a mean of 5.8 days (range, 3-8 days) before PPV (IVI group, n = 12) were younger than PDR patients with a history of PRP (PRP group, n = 29) and untreated PDR patients (control group, n = 21). The duration of diabetes mellitus was similar in the three groups. Label-free quantitative proteomics analysis showed that the signal intensities for fibronectin, fibrinogen α chain, fibrinogen β chain, fibrinogen γ chain, VEGF receptor 1 (VEGFR1), and VEGFR2 were significantly greater in the IVI group than in the other two groups. Enzyme-linked immunosorbent assays validated the results for fibronectin and fibrinogens, but found no significant differences in VEGF or VEGFR2 concentrations. VEGFR1 expression was significantly greater in the IVI and PRP groups than in the control group. CONCLUSIONS: VH fibronectin and fibrinogen concentrations were highest in the IVI patients, which may promote fibrin-fibronectin complexation and fibrosis in eyes with PDR.
引用
- Wei Q, Zhang T, Jiang R, et al. Vitreous Fibronectin and Fibrinogen Expression Increased in Eyes With Proliferative Diabetic Retinopathy After Intravitreal Anti-VEGF Therapy. Invest Ophthalmol Vis Sci. 2017. PMID: 29117316. doi:10.1167/iovs.17-22345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。